Neurocrine wants to develop new obesity drugs. It’s reportedly nearing an acquisition to accelerate that move.

[Jaimy Lee]

Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.

Continue reading...